including dabigatran, rivaroxaban, apixaban, and edoxaban are used for the prevention of stroke and peripheral thromboembolism in NVAF and for treatment and prophylaxis of VTE.
This paper considers any type of OAC treatment available in the countries in focus (either VKA or NOAC
Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs
due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and dose frequencies.
However, a new class of drugs, "new oral anticoagulants" (NOACs
), has become available.
The introduction of new oral anticoagulants (NOACs
) has changed the management of patients with venous and arterial thromboembolic diseases.
have been intensely studied in patients with nonvalvular atrial fibrillation.
Recent reports tell us the NOACs
carry a risk for bleeding between 0.6% and 3.6% annually (Siegal & Crowther, 2012).
The AAN guideline also provides general recommendations on the use of novel oral anticoagulant agents (NOACs
) as alternatives to warfarin.
 Nonstandard abbreviations: NOAC
, novel oral anticoagulant; Dabi, dabigatran; Xa, activated factor X; Riva, rivaroxaban; VKA, vitamin K antagonist; INR, international normalized ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; EQA, external quality assessment; ANOVA, analysis of variance; ISI, international sensitivity index.
 The relevance and applicability of these studies have become more apparent with the advent of the new or direct-acting oral anticoagulants (NOACs
), which work by directly inhibiting thrombin or factor Xa.
Its management includes oral anticoagulants like vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOAC
) and large studies demonstrated that NOACs
are equal to VKAs in stroke prevention have a lower risk of intracranial hemorrhage and a lower overall bleeding risk, but a higher incidence of gastrointestinal bleeding .
The FestWorld Foundation will support the efforts of FEND and National Opioid Action Coalition (NOAC
), a WPP, iHeartMedia, and Fors Marsh Group initiative that complements existing state and federal government efforts to help drive measurable results in prevention, treatment and/or recovery for communities and individuals affected by the opioid crisis.